Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710813 · ClinicalTrials.gov registry record
Alglucosidase Alfa Pompe Safety Sub-Registry
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 110
- Enrollment target
NCT01710813: Completed study, sponsored by Genzyme, a Sanofi Company.
NCT01710813 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01710813 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.
Primary Outcome
collect meaningful data on patients with these outcomes following treatment with alglucosidase alfa
Interventions
- BIOLOGICAL alglucosidase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-03-20 |
| Est. Completion | 2021-04-20 |
What the finished NCT01710813 record still lists
NCT01710813 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which alglucosidase alfa is the first listed.
NCT01710813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01710813 about?
NCT01710813 is a clinical study titled "Alglucosidase Alfa Pompe Safety Sub-Registry". To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.
What is the current status of trial NCT01710813?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2015-03-20. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT01710813?
The interventions under investigation include: alglucosidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT01710813?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI